Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891754539> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2891754539 abstract "e21035 Background: About 20% of metastatic melanomas harbor NRAS mutations which constitutively activate the MAPK pathway, driving cell proliferation and inhibiting apoptosis. The response of patients with NRAS-mutated melanoma to checkpoint inhibitor therapy is so far unknown. A previous study suggested a higher response rate of NRAS-mutated melanoma to anti-PD-1/anti-PD-L1 with an objective response in 7 out of 11 (64%) patients compared to 35% and 21% in BRAF wildtype or BRAF V600-mutated melanoma, respectively. Methods: In total, 224 patients with NRAS-mutated melanoma were analyzed. Of these, 180 patients received ipilimumab, 98 anti-PD1 monotherapy, and one patient combined ipilimumab and anti-PD1 therapy. We evaluated overall response rate (ORR), disease control rate, progression-free survival (PFS) and overall survival to checkpoint inhibitor therapy in these patients. Results: In this patient cohort with NRAS-mutated melanoma, 27% had brain metastases, 62% an elevated LDH and 22% an ECOG > = 1. ORR was 15% for treatment with ipilimumab and 34% for anti-PD1 therapy. Disease control rates were 27% for ipilimumab and 52% for anti-PD1 therapy. PFS was 4.5 months for ipilimumab and 11.4 months for anti-PD1 therapy. Overall survival of all patients was 29 months. Conclusions: The efficacy data of ipilimumab or anti-PD1 therapy in NRAS-mutated melanoma patients were similar to the known response rates of NRAS wildtype melanoma patients." @default.
- W2891754539 created "2018-09-27" @default.
- W2891754539 creator A5034365278 @default.
- W2891754539 creator A5040652983 @default.
- W2891754539 creator A5049264533 @default.
- W2891754539 creator A5056227404 @default.
- W2891754539 creator A5056685282 @default.
- W2891754539 creator A5057381405 @default.
- W2891754539 creator A5064778812 @default.
- W2891754539 creator A5072203765 @default.
- W2891754539 creator A5082278497 @default.
- W2891754539 creator A5089297467 @default.
- W2891754539 date "2017-05-20" @default.
- W2891754539 modified "2023-09-23" @default.
- W2891754539 title "NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts." @default.
- W2891754539 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e21035" @default.
- W2891754539 hasPublicationYear "2017" @default.
- W2891754539 type Work @default.
- W2891754539 sameAs 2891754539 @default.
- W2891754539 citedByCount "1" @default.
- W2891754539 countsByYear W28917545392017 @default.
- W2891754539 crossrefType "journal-article" @default.
- W2891754539 hasAuthorship W2891754539A5034365278 @default.
- W2891754539 hasAuthorship W2891754539A5040652983 @default.
- W2891754539 hasAuthorship W2891754539A5049264533 @default.
- W2891754539 hasAuthorship W2891754539A5056227404 @default.
- W2891754539 hasAuthorship W2891754539A5056685282 @default.
- W2891754539 hasAuthorship W2891754539A5057381405 @default.
- W2891754539 hasAuthorship W2891754539A5064778812 @default.
- W2891754539 hasAuthorship W2891754539A5072203765 @default.
- W2891754539 hasAuthorship W2891754539A5082278497 @default.
- W2891754539 hasAuthorship W2891754539A5089297467 @default.
- W2891754539 hasConcept C121608353 @default.
- W2891754539 hasConcept C126322002 @default.
- W2891754539 hasConcept C143998085 @default.
- W2891754539 hasConcept C21790070 @default.
- W2891754539 hasConcept C2777658100 @default.
- W2891754539 hasConcept C2781187634 @default.
- W2891754539 hasConcept C502942594 @default.
- W2891754539 hasConcept C526805850 @default.
- W2891754539 hasConcept C71924100 @default.
- W2891754539 hasConceptScore W2891754539C121608353 @default.
- W2891754539 hasConceptScore W2891754539C126322002 @default.
- W2891754539 hasConceptScore W2891754539C143998085 @default.
- W2891754539 hasConceptScore W2891754539C21790070 @default.
- W2891754539 hasConceptScore W2891754539C2777658100 @default.
- W2891754539 hasConceptScore W2891754539C2781187634 @default.
- W2891754539 hasConceptScore W2891754539C502942594 @default.
- W2891754539 hasConceptScore W2891754539C526805850 @default.
- W2891754539 hasConceptScore W2891754539C71924100 @default.
- W2891754539 hasLocation W28917545391 @default.
- W2891754539 hasOpenAccess W2891754539 @default.
- W2891754539 hasPrimaryLocation W28917545391 @default.
- W2891754539 hasRelatedWork W1179952421 @default.
- W2891754539 hasRelatedWork W1607072916 @default.
- W2891754539 hasRelatedWork W1804117510 @default.
- W2891754539 hasRelatedWork W1911679611 @default.
- W2891754539 hasRelatedWork W1984899592 @default.
- W2891754539 hasRelatedWork W2052735666 @default.
- W2891754539 hasRelatedWork W2096540669 @default.
- W2891754539 hasRelatedWork W2221230665 @default.
- W2891754539 hasRelatedWork W2427873479 @default.
- W2891754539 hasRelatedWork W2533139534 @default.
- W2891754539 hasRelatedWork W2547428353 @default.
- W2891754539 hasRelatedWork W2743762084 @default.
- W2891754539 hasRelatedWork W2751176308 @default.
- W2891754539 hasRelatedWork W2885442085 @default.
- W2891754539 hasRelatedWork W2902541417 @default.
- W2891754539 hasRelatedWork W2973085643 @default.
- W2891754539 hasRelatedWork W3014641112 @default.
- W2891754539 hasRelatedWork W3135344087 @default.
- W2891754539 hasRelatedWork W3169668313 @default.
- W2891754539 hasRelatedWork W3201926698 @default.
- W2891754539 isParatext "false" @default.
- W2891754539 isRetracted "false" @default.
- W2891754539 magId "2891754539" @default.
- W2891754539 workType "article" @default.